Toxoplasmosis is a rare but severe complication after allogenic hematopoietic stem cell transplantation (allo-HSCT) that, in the vast majority of cases, develops as a reactivation of a latent infection;
1,2 however primary infection is also possible. [2] [3] [4] Patients who were toxoplasmosis seropositive before transplantation are at higher risk when the donor is seronegative. 1, 4, 5 Toxoplasmosis disease is associated with high morbidity and mortality rate in~60-90% when the onset is early after transplantation. [4] [5] [6] In most cases, patients develop localised central nervous system infection, but disseminated disease is also possible. 1, 5, 7 In adult patients who undergo HSCT, the reported incidence of toxoplasmosis is~1% with an important variability between geographic areas depending on seroprevalence. 1 When screening PCR is performed in patients at high risk of infectious complications, the incidence of infection (without disease) is 12-18%. [1] [2] [3] Here, we report the frequency of toxoplasmosis disease, its presentation, diagnosis and outcome in paediatric patients who underwent allogeneic HSCT in the Paediatric Haematology and Oncology Department at Fondazione IRCCS Policlinico San Matteo of Pavia between 1 January 2011 and 31 December 2015. HSCT data and medical records were collected retrospectively. All patients and, when possible, all donors were tested before and after transplant in order to assess their immunological status with LIAISON XL Toxo-IgG II/IgM (DiaSorin, Saluggia, Italy). In all suspected cases VIDAS TOXO-IgG II and IgG AVIDITY, Toxo-ISAGA IgM (Biomerieux, Marcy l'Etoile, France), ETI-ToxoA (DiaSorin) were performed. To assess their humoral immunological status and in house Interferon Gamma Release Assay, QuantiFERON-ELISA (Cellestis Limited, Carnegie, Victoria, Australia), with Toxoplasma antigen (kindly provided by Diasorin) was also used. The commercial real-time PCR test ELITE-MGB (ELITech Group, Torino Italia) was performed on peripheral blood, and/or cerebrospinal fluid in all the suspected cases and was also used to monitor the recovery.
The 187 allo-HSCTs analysed in the study included 15 second allo-HSCT (8%) and 5 patients who received a previous auto-HSCT. Mean age at transplant was 9 years. Underlying disease included malignant (66.3%) and non-malignant (33.7%) disorders. 
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In 152 cases when both donor and recipient data were available, we could define donor/recipient serology combinations. Donor-seronegative/recipient-seronegative patients (D − /R − ) were 55.2%, D+/R − were 15.1%, D+/R+ were 7.9% and the group at higher risk for toxoplasmosis, D − /R+, included 21.7% (33/152) pairs.
In our series, the cumulative incidence of toxoplasmosis disease was 2.1%, with 4 cases out of 187 transplants. The first patient, an Italian 16-year-old boy with myelodysplastic syndrome, developed a severe, steroid refractory grade IV aGvHD with intestinal involvement and recurrent infections (viral and fungal); cerebral toxoplasmosis was diagnosed 9 months after transplant and soon after he died because of multi-organ failure; case two was a 14-year-old Romanian girl with acute myeloid leukaemia, who was diagnosed with cerebral toxoplasmosis on day 55 from haploidentical HSCT treated successfully with high doses of IV cotrimoxazole plus folinic acid in the acute phase, and then shifted to oral pyrimetamine/sulfadiazine combination; the third case was a 5-year-old Rumanian child with a non-Hodgkin lymphoma who received transplant from a MUD, complicated by severe adenovirus typhlitis and BK virus reactivation that impaired engraftment; on day 55 he developed disseminated toxoplasmosis that caused death and he died at day 58 because of neuro-respiratory complications.
Case 4 was a young Italian boy with myelodysplastic syndrome who received a diagnosis of toxoplasmic chorioretinitis before starting the conditioning regimen and in whom pre-transplant treatment was successful in preventing reactivation during engraftment period. Main characteristics of four patients are summarised in Table 2 . In our cohort, in accordance with literature data, all patients who developed toxoplasmosis were toxo-IgG positive before HSCT; three of them were transplanted from a toxoplasma IgG-negative donor; donor's toxoplasma serology was not tested in one case. In the two fatal cases the IGRA test never became positive.
Pre-HSCT seropositivity is the most important risk factor for toxoplasma disease in the post-transplant period, via reactivation.
As recently reported in the review by Gajurel et al., 9 on allo-HSCT, patients who developed toxoplasmosis were mostly seropositive pre-transplant (73%) and only 8% were documented as being truly seronegative. In our cohort of paediatric transplants seroprevalence was 28.8%, higher than expected in the Italian population, due to the high number of patients coming from Eastern Europe. 10 A recent report that analysed toxoplasma seroprevalence in the Western Romanian population, for example, has demonstrated a prevalence increasing with age, ranging from 35.0 to 76.8%. 11 Therefore, performing pre-transplant serology is strongly recommended, irrespective of the expected rate of seropositivity.
The main risk factor for reactivation is immune suppression with a higher incidence of toxoplasmosis seen in cord blood, haploidentical and unrelated mismatched donor HSCT. 8, 12, 13 Low CD4+ cell count, myeloablative conditioning, TBI and use of antithymocyte globulin have also been associated with reactivation. 4, 12, 13 GvHD is seen in 59% of allo pre-transplant seropositive patients, but has not been consistently associated with reactivation. 3, 13 Prophylaxis to prevent toxoplasma reactivation has been recommended in HSCT recipients, with different dosing regimens that vary from daily to twice weekly regimens 4 but is not followed consistently, as evidenced by several case reports and observational studies, 4, 5 mainly because of myelosuppressive effects of trimethoprim-sulfamethoxazole, the most commonly used prophylactic agent.
In our department patients receive trimethoprim-sulfamethoxazole twice weekly during conditioning regimen, after engraftment and until CD4+ cell recovery.
At the time of diagnosis of toxoplasmosis patient 1 had been on prophylaxis for several months, while patient 2 for only 10 days. Patient 3 never started trimethoprim-sulfamethoxazole administration because he never reached engraftment. As previously reported the patient with the isolated cerebral toxoplasmosis recovered, whereas the patients with disseminated toxoplasmosis died.
14 This highlights the need for prompt diagnosis and early treatment. Unfortunately, early diagnosis requires a high index of suspicion, because, at the onset of toxoplasma infection, patients commonly present non-specific symptoms. Otherwise, in cerebral toxoplasmosis, clinical, cerebrospinal fluid analysis and magnetic resonance imaging findings are non-specific and may not allow for a distinction between toxoplasmosis, mold infections or manifestations of post-transplant lymphoproliferative disease.
Serological assays are useful to identify patients at risk before transplantation but are of limited value in diagnosing reactivation due to intense immunosuppressive treatment resulting in reduction of total antibody amount.
Introduction of highly sensitive PCR techniques for the demonstration of Toxoplasma gondii DNA in blood and/or liquor has increased our diagnostic power resulting in a higher rate of toxoplasmosis identified in HCT recipients. Given that there is a not negligible incidence of toxoplasmosis disease in our population, we decided to implement in our department a screening protocol with the aim of diagnosing patients in the early phase of disease prior to onset of symptoms to allow prompt therapy administration as recommended by other authors. 9, 13, 15 According with our laboratory of Parasitology, we designed a screening protocol consisting of the pre-transplant assessment of toxoplasma serologic assays for class IgG, IgM and IgA antibodies of every pair donor/recipient; all positive recipients with a seronegative donor, will undergo real-time PCR screening on peripheral blood starting on the day of stem cells infusion, every 15 days during the engraftment period and subsequently every 3 months until CD4+ cell recovery occurs. Cerebrospinal fluid or other tissue samples will be examined when clinically indicated. Also IGRA test to evaluate the specific T-cell immunity will be performed during the same period.
In the future we will analyse the impact of this strategy in reducing the incidence and the burden of toxoplasmosis disease in this particular subset of immunocompromised patients.
